LONG MINI-FUTURE - MODERNA | Delayed Deutsche Boerse AG 08:02:27 2024-07-08 EDT | ||
| 8.04 EUR | +1.90% |
|
| Current month | -2.23% | ||
| 1 month | -29.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 8.04 | +1.90% |
| 24-07-05 | 7.89 | +1.15% |
| 24-07-04 | 7.8 | +0.26% |
| 24-07-03 | 7.78 | -1.39% |
| 24-07-02 | 7.89 | +1.41% |
Delayed Quote Deutsche Boerse AG
Last update July 08, 2024 at 08:02 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VP76A6 |
| ISIN | DE000VP76A62 |
| Date issued | 2020-09-09 |
| Strike | 32.27 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.13 € |
|---|---|
| Lowest since issue | 2.65 € |
| Spread | 0.03 € |
| Spread % | 0.37% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Certificates
- Certificat
